pathological mechanism behind JCAD and coronary artery disease is independent of the established risk factors from the association analysis. Because JCAD is a cell-cell junctionassociated protein expressed in endothelial cells, we speculate that JCAD plays a significant role in angiogenesis as observed in other endothelial adhesion molecules. [4] [5] [6] [7] Angiogenesis plays an important role in number of physiological and pathological processes, including atherosclerosis, diabetic retinopathy, tumor growth, and inflammation. Endothelial cell-cell junctions, critical for vascular integrity and maintenance of vascular function, are regulated by a complex signaling network. For example, VE-cadherin, a major regulator of endothelial adherens junctions, controls multiple signaling cascade and angiogenesis. 7 However, molecular mechanisms that regulate angiogenesis are not fully understood although accumulating recent investigations. [8] [9] [10] To elucidate the role of JCAD/KIAA1462 in physiological/pathological angiogenesis, we generated the KIAA1462 
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Generation of mKIAA1462 −/− Mice
We generated mice lacking mouse JCAD protein, a gene product of mKIAA1462. A targeting vector was designed to disrupt the mKIAA1462 gene by replacing most of exon 3 encoding aa 165 to 1272 of JCAD with neomycin-resistant gene ( Figure IA in the online-only Data Supplement). Genomic DNA was isolated from tail, and substitution of the targeted region by homologous recombination was confirmed by Southern blotting (data not shown) and polymerase chain reaction ( Figure IB in the online-only Data Supplement). The mRNA from first 2 exons were detected at expected size, but exon 3 was undetectable in mKIAA1462 −/− mice, indicating that depleting of exons was accurate as designed ( Figure Figure 1A ). We monitored food intake to confirm that the lower body weight of mKIAA1462 −/− is not attributable to lower food consumption. We compared food intake of WT at 8 weeks and mKIAA1462
−/− at 10 weeks to have similar body weight (24.2±0.63 versus 23.8±1.4 g). Averaged daily food intake per mouse was similar between mKIAA1462 −/− and +/+ mice in both males and females ( Figure 1B ).
Physiological Vascular Development and Permeability Were Preserved in mKIAA1462 −/− Mice
To examine whether knockdown of JCAD influences the physiological development of blood vessels, we assessed the retinal vasculature in WT and mKIAA1462 −/− mice. Fluorescein angiography showed no apparent differences in retinal vascular network (large vessels sprouting, branching vessels, tortuosity, vessel dilatation, and hemorrhages) between WT and mKIAA1462 −/− mice ( Figure 1C ). In vivo permeability assay using Evans blue dye demonstrated no significant difference of vascular permeability between WT and mKIAA1462 −/− mice in multiple organs ( Figure 1D ).
Decreased Tumor Growth and Angiogenesis in mKIAA1462 −/− Mice
It has been recognized that tumor growth is dependent on angiogenesis. 5, 11 To explore the role of JCAD in pathological angiogenesis in vivo, the tumor growth was monitored after the subcutaneous injection of B16F10 melanoma cells. Immunostaining of microvessels by endothelial cell marker (CD31) showed decreased CD31-positive vascular structure in tumor sections of mKIAA1462 −/− than WT (P<0.05; Figure 2C and 2D). To assess the maturity of tumor microvessels, smooth muscle actin (SMA) was costained with CD31 because mature microvessels are covered by SMA-positive pericytes. 12, 13 Mature microvessels in tumor sections (CD31 and SMA-double positive) was significantly lower in mKIAA1462 −/− mice than in WT (P<0.05; Figure 2E ). To compare the vessel maturity in the similar tumor size, we compared B16F10 tumors at day 15 from WT and day 18 from mKIAA1462 −/− mice (tumor size; 8545±706 mm 3 for day 18 knockout mice versus 7542±593 mm 3 for day 15 WT mice; P=not significant). The SMA-positive mature microvessels in day 18 tumor in knockout mice were also smaller than day 15 tumor in WT mice and similar with day 15 tumor in knockout mice ( Figure 2D and 2F), indicating that less matured microvessels in mKIAA1462 −/− mice were not tumor size dependent.
We also analyzed tumor growth using LLC (Lewis lung carcinoma) lung carcinoma cell and E0771 breast cancer cell line. Significantly impaired tumor growth and tumor angiogenesis in both cell lines were also observed (Figure 2F 
mKIAA1462 −/− Mice Exhibited Decreased Neovascularization in Matrigel Plug Assay
For quantitative assessment of in vivo angiogenic potential in mKIAA1462
−/− mice, we implanted Matrigel plugs in the flank region. The degree of angiogenesis within the implants can be quantified by measuring the hemoglobin content of the resected Matrigel. 5 The hemoglobin content of resected Matrigel at day 7 after the implantation showed 59% decrease in mKIAA1462 −/− mice than in WT mice (P<0.05; n=4-5 in each group; Figure 3A and 3B).
Reduced Endothelial Sprouting in Aortic Ring of mKIAA1462 −/− Mice
To analyze the role of JCAD during blood vessel sprouting, we next used the aortic ring assay. As shown in Figure 3C , the aortic ring cultures isolated from mKIAA1462 −/− mice exhibited significantly reduced endothelial cell sprouting when compared with WT.
Expression of JCAD in Cultured Human Endothelial Cells and Intracellular Localization
We first examined the expression of JCAD in various cultured human endothelial cell lines by real-time polymerase chain reaction and Western blotting. Expression of JCAD in both of mRNA and protein levels is detected in all of cultured human endothelial cells ( Figure 4A ). We examined intracellular localization of JCAD in human umbilical vein endothelial cells by immunofluorescence microscopy. In a sparse condition, the signal for JCAD was observed in peripheral membrane ruffles and in perinuclear regions ( Figure 4B ). After vascular endothelial growth factor (VEGF) stimulation, JCAD was observed in peripheral membrane ruffles and merged with the signal for VEGFR (VEGF receptor). JCAD expression was mainly observed at perinuclear region before forming cell-cell contact as VE-cadherin; however, localization of JCAD changes to cell-cell junctions and colocalized with VE-cadherin after confluence as observed in mouse endothelial cell line 3 ( Figure 4C ). VEGF stimulation in confluent cell layer induced small gaps of JCAD at cell-cell junctions ( Figure 4D ), similar with VEGF-induced gaps of VE-cadherin as reported in previous studies.
14,15 We also assessed the expression level of JCAD after the VEGF stimulation in whole-cell lysate of confluent human umbilical vein endothelial cells. Expression level of JCAD in human umbilical vein endothelial cells was not altered by the VEGF stimulation ( Figure 4E) . 
Impairment of Cell Proliferation, Wound Healing, and Cord Formation by Knockdown of JCAD In Vitro
The results from in vivo experiments demonstrated that knockdown of JCAD inhibits angiogenesis. To confirm that impaired angiogenic capacity is accounted by the loss of function of JCAD in endothelial cells, we performed proliferation, migration, and cord formation assay in cultured endothelial cells. Western blot analysis demonstrated that JCAD was effectively knocked down by small interfering RNA ( Figure 5A ). Because cell migration is an essential step in angiogenic response, we assessed the effect of JCAD deficiency on endothelial cell migration. Proliferation assessed by WST-1 (water soluble tetrazolium salts) assay showed impaired proliferation by knockdown of JCAD (P<0.05; Figure 5B ). BrdU (bromodeoxyuridine) incorporation into human umbilical vein endothelial cells was also decreased by knockdown of JCAD (P<0.05; Figure 5C ), whereas no significant difference was observed in cell survival assessed by Trypan blue assay ( Figure 6D ). Wound-healing assay demonstrated impaired cell directional migration by knockdown of JCAD by siRNA (P<0.05; Figure 5E ). Knockdown of JCAD also inhibited cord formation capacity (P<0.05; Figure 5F ). To further define the VEGFinduced signaling pathways for angiogenesis, we examined the effect of knockdown of JCAD on the phosphorylation of Akt and extracellular signal-regulated kinase (ERK). The phosphorylation of Akt was unchanged by the knockdown of JCAD; however, phosphorylation of ERK and VEGFR2 was significantly reduced by knockdown of JCAD (P<0.05; Figure 5G ). Expression level of VEGFR2 was also inhibited by knockdown of JCAD. These data are compatible with preserved cell survival but impaired cell proliferation by the knockdown of JCAD because Akt signaling pathway mediates cell survival 16 and ERK-signaling pathway mediates cell proliferation. [17] [18] [19] These in vitro data supported our hypothesis that JCAD in endothelial cells regulates angiogenesis.
Discussion
In this study, we demonstrated that (1) mKIAA1462 −/− exhibited no apparent changes in vascular morphology by light microscopy, in vivo vascular permeability, and retinal angiography, (2) impaired tumor growth and angiogenesis in mKIAA1462 −/− mice, and (3) in vitro angiogenic capacities (endothelial cell migration, cord formation, and proliferation) were decreased by the knockdown of JCAD in cultured endothelial cells. These findings suggest that JCAD function in physiological angiogenesis is redundant, but JCAD plays a significant role in pathological angiogenesis. 5 etc) play a significant role in angiogenesis. Therefore, those molecules might have some degrees of overlapping roles and might compensate each other for its deletion in vivo during mouse embryogenesis, resulting in normal physiological angiogenesis as observed in the present study. 5, 6 The other important finding of our study is that tumor neovascularization showed immature microvessels. Tumor microvessels in mKIAA1462
−/− showed decreased coverage by α SMA-positive pericyte. Because plaque angiogenesis is an established process of plaque growth and plaque instability, recent genome-wide association study findings of JCAD/KIAA1462 as a locus of coronary artery disease and myocardial infarction 1,2 might be accounted for impaired angiogenic ability from vasa vasorum. Immaturity of plaque microvessels is a source of intraplaque hemorrhage. [23] [24] [25] Recent study reported that plaque hemorrhage was observed in plaques with high density of immature microvessels that lack SMA-positive mural cells. 25 Future studies directly investigating the role of JCAD in plaque angiogenesis and plaque stability are desired to clarify the association between loss of function of JCAD and coronary artery disease and myocardial infarction.
JCAD/KIAA1462 was identified as a locus of coronary artery disease 1, 2 ; however, recent genetic studies demonstrated that JCAD/KIAA1462 is also a candidate gene for late-onset Alzheimer disease, 26 serous borderline ovarian tumor, 27 and laying performance in geese. 28 However, biological investigation of the function of this gene product, known as JCAD, is uncharacterized further after Akashi et al 3 reported that JCAD is expressed at cell-cell junction. Our study revealed the role of JCAD in pathological angiogenesis, which may account partially for plaque instability. Further studies are needed to elucidate the functions of JCAD to understand its role in other diseases such as Alzheimer disease or ovarian tumor.
The precise mechanisms underlying the attenuated angiogenesis by JCAD deletion remain unclear in the present study. JCAD contains a proline-rich region but does not seem to have any functional domains that can interact with intracellular molecules. Given the colocalization and association of JCAD/ KIAA1462 with VE-cadherin in endothelial cells, we speculate that JCAD/KIAA1462 may potentiate a part of angiogenic properties of VE-cadherin. Our data indicate that JCAD/KIAA1462 acts as an intracellular signaling molecule in the angiogenic processes. We showed that the VEGF-induced proliferation, phosphorylation of ERK, and expression level of VEGFR2 were decreased by knockdown of JCAD. Because VE-cadherin interacts with VEGFR2 phosphorylation and regulates its downstream proliferation ERK signaling, 29 JCAD may be involved in this process by forming a complex with VE-cadherin and VEGFR2. Further studies are required to clarify the detailed cellular function and signaling of JCAD/KIAA1462 in the homeostasis of endothelial cells and angiogenesis.
In conclusion, in vitro experiments demonstrated that JCAD has a significant role in endothelial migration, proliferation, and cord formation. Knockdown of JCAD unchanged physiological vessel development in vivo, indicating that other endothelial adhesion molecules compensated for its loss. However, JCAD seems to have a significant role in pathological angiogenesis and microvessel maturity. Impaired maturity by loss of function of JCAD might be one of the mechanisms responsible for the association between JCAD and coronary artery disease and myocardial infarction in clinical population as recent genome-wide association study findings revealed.
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